昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06127 昭衍新药

交易中 09-24 15:53:31

27.240

-0.320

-1.16%

最高29.300	最低27.020	成交量583.03万
今开27.880	昨收27.560	日振幅8.27%
总市值204.03亿	流通市值32.41亿	总股本7.49亿
成交额1.65亿	换手率4.90%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":27.24,"timestamp":1790236410930,"preClose":27.56,"halted":0,"volume":5830301,"delay":0,"changeRate":-0.011611030478955018,"floatShares":118995206,"shares":749000000,"eps":0.467363137254902,"marketStatus":"交易中","change":-0.32,"latestTime":"09-24 15:53:31","open":27.88,"high":29.3,"low":27.02,"amount":164789158,"amplitude":0.082729,"askPrice":27.26,"askSize":700,"bidPrice":27.24,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.5595358738509804,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1790237400000},"marketStatusCode":2,"adr":0,"listingDate":1614268800000,"exchange":"SEHK","adjPreClose":27.56,"dividendRate":0.005059,"openAndCloseTimeList":[[1790213400000,1790222400000],[1790226000000,1790236800000]],"volumeRatio":0.934199,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":46.39,"timestamp":1790233200000,"preClose":47.77,"halted":0,"volume":41845300,"delay":0,"premium":"-49.74"}},"requestUrl":"/m/hq/s/06127","defaultTab":"news","newsList":[{"id":"2669322324","title":"昭衍新药（603127）9月23日主力资金净买入1.25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669322324","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669322324?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:18","pubTimestamp":1790209123,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，昭衍新药报收于47.77元，上涨3.58%，换手率7.96%，成交量49.96万手，成交额23.98亿元。9月23日的资金流向数据方面，主力资金净流入1.25亿元，占总成交额5.22%，游资资金净流出5953.8万元，占总成交额2.48%，散户资金净流出6569.04万元，占总成交额2.74%。融券方面，融券卖出4.1万股，融券偿还100.0股，融券余量26.03万股，融券余额1243.45万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","603127","BK1576","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138552732","title":"昭衍新药（06127）5.4亿元闲置资金再投中信系理财 构成披露交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1138552732","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138552732?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:58","pubTimestamp":1790153904,"startTime":"0","endTime":"0","summary":"2026年9月23日，北京昭衍新药研究中心股份有限公司公告称，旗下全资子公司北京昭衍管理科技有限公司于2026年4月20日至2026年9月23日期间，通过中信证券股份有限公司及其附属公司合计认购7项金融产品。截至公告日，上述产品中尚未到期的投资本金合计5.4亿元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669101886","title":"昭衍新药(06127.HK)附属近期仍未到期的中信证券金融产品合计投资金额为5.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669101886","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669101886?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:55","pubTimestamp":1790153729,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1147","06030","BK1564","LU1794554557.SGD","LU1720050803.USD","BK1521","BK1516","BK1576","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669910137","title":"昭衍新药：认购中信证券金融产品 投资金额5.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669910137","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669910137?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:53","pubTimestamp":1790153580,"startTime":"0","endTime":"0","summary":"南财智讯9月23日电，昭衍新药（06127.HK）发布须予披露交易公告，于2026年4月20日至2026年9月23日期间，公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品，合计投资金额为人民币5.4亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882481581.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882481581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU1997244956.HKD","LU1794554557.SGD","06127","BK0188","BK1576","BK1564","BK0196","LU2495084118.USD","BK1141","LU1328615791.USD","LU2580892789.USD","LU1781817850.SGD","LU0405327494.USD","BK0012","LU1580142542.USD","LU1655091616.SGD","06030","BK0028","159940","LU1997245177.USD","600030","LU0405327148.USD","LU1146622755.USD","BK1521","LU2148510915.USD","LU2289578879.USD","BK0216","LU1720050803.USD","BK1516","LU1064131003.USD","LU1820825898.SGD","LU1255011170.USD","BK0183","BK0276","BK1147","603127","LU1997245094.SGD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669056771","title":"港股异动 | 昭衍新药(06127.HK)涨超4% 上半年新签订单接近翻倍 公司两大基地产能建设持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2669056771","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669056771?lang=zh_cn&edition=full","pubTime":"2026-09-23 15:28","pubTimestamp":1790148490,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669174258","title":"CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669174258","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669174258?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:40","pubTimestamp":1790134800,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端CRO概念股早盘多数走高，截至发稿，金斯瑞生物科技（01548）上涨4.70%，报42.36港元；昭衍新药（06127）上涨4.45%，报27.70港元；康龙化成（03759）上涨2.51%，报31.02港元；泰格医药（03347）上涨0.82%，报46.96港元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-23/doc-inisusyi5326555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603127","HK0000320264.USD","HK0000320223.HKD","BK0216","HK0000306685.HKD","HK0000306701.USD","06127","01548","BK1583","BK1141","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156665","title":"智通AH统计|9月21日","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156665","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669156665?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:15","pubTimestamp":1789978506,"startTime":"0","endTime":"0","summary":"东北电气0.2392.251029.71%-19.83%浙江世宝3.90015.58378.46%-5.26%安德利果汁20.06077.99365.70%87.17%弘业期货2.2008.14343.18%22.10%晨鸣纸业0.6102.06304.92%28.60%中石化油服0.6702.25302.99%-0.92%南京熊猫电子股份3.1259.95281.44%20.56%钧达股份12.42038.77273.91%50.18%京城机电股份2.6108.12272.80%19.86%复旦张江2.6508.19270.19%-11.18%. 安德利果汁20.06077.99365.70%87.17%新华文轩8.06015.29127.17%59.28%钧达股份12.42038.77273.91%50.18%国民技术8.87522.51203.77%29.71%晨鸣纸业0.6102.06304.92%28.60%沃尔核材8.99517.19128.90%24.73%广合科技123.000185.9381.07%23.84%弘业期货2.2008.14343.18%22.10%美格智能19.88046.47179.98%21.66%南京熊猫电子股份3.1259.95281.44%20.56%. 备注：以上数据由智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；偏离值为当前溢价率与该股过去30天平均溢价率的差值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01989","EWH","00187","00300","02701","01033","02768","03200","03968","06745","00811","82846","03986","02846","LU0607220059.USD","02899","83188","02359","00553","01057","06166","02827","02475","01877","03143","83130","LU2097828631.EUR","00042","06821","03188","02218","03750","06127","159982","LU0516422440.USD","07233","03308","02338","03130","09981","02865","03678","03328","00991","00317","01349","399300","03268","01812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0348766576.USD","BK1161","03347","LU1880383366.USD","LU3063872942.SGD","LU0561508036.HKD","603127","HK0000306701.USD","LU0029874905.USD","LU0359202008.SGD","BK1141","LU0540923850.HKD","LU1242518857.USD","BK1583","LU1794554557.SGD","LU0043850808.USD","LU0516422440.USD","LU0516422366.SGD","BK1515","LU0588546209.SGD","02359","LU0516422952.EUR","01548","LU0348825331.USD","LU0051755006.USD","BK1589","09939","03759","HK0000320223.HKD","06127","LU0307460666.USD","LU2242644610.SGD","CXO","159938","LU2125910500.SGD","SG9999002463.SGD","01873","LU0516423091.SGD","KURE","02269","LU0359201612.USD","LU0456846285.SGD","LU0052750758.USD","LU0516423174.USD","WX","LU0039217434.USD","BK1610","LU0029874061.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668191239","title":"港股午评|恒生指数早盘涨0.67%     AI制药板块大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2668191239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668191239?lang=zh_cn&edition=full","pubTime":"2026-09-18 12:00","pubTimestamp":1789704004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.67%，涨164点，报24768点；恒生科技指数涨1.74%。港股早盘成交1070亿港元。十部门印发医药十五五规划，机构看好医药迎“Claude”时刻。AI制药进入战略入局阶段。曦智科技-P涨超17%。天数智芯涨超13%，公司有望持续受益AI资本开支的增长及算力自主可控浪潮。MINIMAX-W涨13%，旗下多款产品通过Singtel AI Pass纳入配套订阅计划。俊知集团涨超10%，收购青海中利光纤技术有望打开AI算力相关光纤产品增量空间。大股东解禁期满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0264606111.USD","603127","LU0972618739.USD","LU0862451837.USD","07666","LU1366334651.USD","03033","BK1544","513600","BK1592","LU1831875114.USD","02228","BK1161","BK1506","07552","09067","LU0463099449.HKD","LU0791591158.USD","02833","07200","00992","HK0000320223.HKD","BK1526","HSTECH","LU2242644610.SGD","IE0003895053.USD","07300","03423","BK1149","LU0791590937.USD","HK0000320264.USD","01879","09088","LU1366334578.USD","06658","83115","IE00B0JY6N72.USD","LU0862451753.SGD","LU1808992512.USD","LU0244354667.USD","LU0048580855.USD","LU0181495838.USD","07500","03067","BK1193","LNVGY","LU0320764755.SGD","LU0672654166.SGD","09903","LU0828237940.HKD","03032","BK1574","00100","02837","BK1117","LU0348825331.USD","03115","LU0417516902.SGD","LU0052756011.USD","LU0348827113.USD","LU1267930227.SGD","02701","BK1141","BK1583","03088","HK0000306701.USD","BK1183","BK1237","LU0890818403.SGD","LU0543330483.HKD","BK1617","80992","LU0310800965.SGD","BK1163","IE0034224299.USD","BK1198","LU0049112450.USD","01300","82800","BK1576","LU0128525689.USD","01818","IE0032431581.USD","09115","LU0140636845.USD","LU0572940350.SGD","HHImain","03696","BK1607","TCHI","LU1785774172.SGD","03419","LU0572939691.SGD","07630","03037","LU1046422090.SGD","02800","LU1235295612.USD","LU0128522157.USD","LU0326950275.SGD","07226","HSI","LU0561508036.HKD","600547","01787","02656","02670","HK0000306685.HKD","06127","LU0029875118.USD","300077","LU1188198961.HKD","02142","MCHmain","LU0370786039.SGD","BK1197","03417"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919445","title":"港股异动 | 生物医药股悉数走高 十部门印发医药十五五规划 机构看好医药迎“Claude”时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919445","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919445?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:04","pubTimestamp":1789697085,"startTime":"0","endTime":"0","summary":"消息面上，工信部等十部门联合发布《医药工业发展\"十五五\"规划》，提出到2030年的发展目标：生物医药研发应用稳居世界前列，创新驱动效能充分释放，重点领域关键核心技术实现系统性突破，生物医药产业加速成为国家新兴支柱产业。浙商证券表示，高频迭代短期将会带来验证阶段需求的井喷，但长期来看，高速迭代可能会带来平台能力的提升和泛化，能够持续迭代的发现平台能力提升或是行业的核心，医药行业的Claude也许将要到来。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1583","BK1588","XBI","BK1574","161726","LU2488822045.USD","159938","01672","07666","399441","09688","BK4581","09939","BK1576","KCAI","BK4588","BK1161","02142","06127","VXUS","BK1141","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919819?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0456846285.SGD","LU0051755006.USD","LU0828237510.HKD","01548","LU0039217434.USD","LU0181495838.USD","LU0588546209.SGD","KURE","LU0561508036.HKD","02359","LU0634319403.HKD","06127","LU0228659784.USD","LU3063872942.SGD","LU1251922891.USD","LU1880383366.USD","LU0856984785.SGD","LU1719994722.HKD","LU2039709279.SGD","WX","LU1242518857.USD","06821","LU0320764243.SGD","LU0359202008.SGD","BK0216","01873","LU0320764599.SGD","SG9999002562.SGD","03347","LU0348735423.USD","LU1242518931.SGD","02269","LU1688375341.USD","603127","CXO","LU0052750758.USD","LU0348827113.USD","BK1161","BK1521","LU0029874905.USD","LU2242644610.SGD","06160","BK1588","LU0348825331.USD","LU0469268626.HKD","BK1610","LU0029874061.USD","LU0516423174.USD","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668580019","title":"剂泰科技-P午前涨逾14% 携手昭衍新药打造mRNA药物创新研发与产业化制造平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2668580019","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668580019?lang=zh_cn&edition=full","pubTime":"2026-09-17 11:28","pubTimestamp":1789615680,"startTime":"0","endTime":"0","summary":"模拟交易客户端剂泰科技-P盘中涨超16%，截至发稿，股价上涨13.79%，现报15.68港元，成交额1.53亿港元。近日，据剂泰科技官微消息，公司与昭衍生物正式签署合资协议，共同设立合资公司昭泰智药，携手打造mRNA药物创新研发与产业化制造平台。根据协议，剂泰科技将在上游提供设计与递送能力，NanoForge已实现对人体内8个关键器官与组织的靶向递送。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-17/doc-inisayan9411675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","BK1141","07666","BK1161","603127","06127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668930750","title":"创新药概念走强 金斯瑞生物科技（01548）涨超15% 机构指医药行业基本面持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2668930750","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668930750?lang=zh_cn&edition=full","pubTime":"2026-09-17 10:29","pubTimestamp":1789612152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念走强，截止发稿，金斯瑞生物科技 涨15.29%，维亚生物涨6.32%，凯莱英涨6.08%，泰格医药涨4.86%，昭衍新药涨4.96%。消息面上，国信证券表示，2026年上半年医药行业收入保持稳健增长，利润端实现双位数增长，26Q2盈利增速进一步提升，创新药及产业链维持较高景气。整体来看，2026年上半年医药行业基本面持续改善，盈利修复趋势进一步确认，创新药及CXO等高景气方向表现突出。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1191","HK0000320223.HKD","BK1141","LNGR","01548","BK1161","06821","HK0000306701.USD","BK1576","BK1574","HK0000320264.USD","HK0000306685.HKD","06127","159992","MEDX","IBBQ","03347","BK1583","01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668930643","title":"港股异动 | 剂泰科技-P(07666.HK)盘中涨超11% 携手昭衍新药打造mRNA药物创新研发与产业化制造平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2668930643","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668930643?lang=zh_cn&edition=full","pubTime":"2026-09-17 10:06","pubTimestamp":1789610811,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07666","BK1576","BK1141","06127","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667050229","title":"每周股票复盘：昭衍新药（603127）Q3盈利将显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2667050229","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667050229?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:15","pubTimestamp":1789233312,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，昭衍新药报收于41.37元，较上周的42.94元下跌3.66%。本周，昭衍新药9月9日盘中最高价报44.08元。三季度稳步改善，四季度因高价订单集中结转，营收与利润率将显著提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK1141","BK0216","603127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374812","title":"股市必读：昭衍新药（603127）9月8日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374812?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:26","pubTimestamp":1788884780,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，昭衍新药报收于43.62元，上涨1.87%，换手率5.74%，成交量36.06万手，成交额15.58亿元。交易信息汇总资金流向9月8日主力资金净流入7016.98万元，占总成交额4.5%；游资资金净流入1.28亿元，占总成交额8.24%；散户资金净流出1.99亿元，占总成交额12.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900001285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","06127","BK0216","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665379322","title":"昭衍新药：9月8日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665379322","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665379322?lang=zh_cn&edition=full","pubTime":"2026-09-08 23:01","pubTimestamp":1788879699,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月8日昭衍新药发布公告称公司于2026年9月8日召开业绩说明会。昭衍新药2026年中报显示，上半年度公司主营收入7.04亿元，同比上升5.27%；归母净利润7.48亿元，同比上升1126.8%；扣非净利润6.99亿元，同比上升2931.69%；其中2026年第二季度，公司单季度主营收入3.88亿元，同比上升1.69%；单季度归母净利润5.09亿元，同比上升2469.84%；单季度扣非净利润4.81亿元，同比上升18544.78%；负债率17.09%，投资收益558.44万元，财务费用-2360.59万元，毛利率23.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800038211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","06127","BK1576","603127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378399","title":"猴价是否还将上涨？“猴茅”昭衍新药总经理最新回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378399","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665378399?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:40","pubTimestamp":1788867600,"startTime":"0","endTime":"0","summary":"对此，昭衍新药董事、总经理兼董事会秘书高大鹏在9月8日的2026年半年度业绩说明会上给予了回应。2026年上半年，昭衍新药营业收入为7.04亿元，同比仅增长5.27%；净利润为7.48亿元，同比增长1126.8%。在对实验猴价格有较大影响的进口政策和供给约束方面，高大鹏回应称，目前进口政策已放开，种猴和商品猴均可进口，从实际情况看，今年非人灵长类进口以商品猴为主。9月8日，昭衍新药股价以43.62元/股报收，最新市值为298亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-08/doc-inircmeq9296831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","603127","BK0216","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342360","title":"午评：沪指半日涨0.36% 农业板块强势领涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342360","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665342360?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:22","pubTimestamp":1788844922,"startTime":"0","endTime":"0","summary":"　　9月8日，三大指数涨跌不一，沪指表现较强。　　板块方面，农业板块反复活跃，亚盛集团4连板，苏垦农发、敦煌种业、中粮科技、华康股份涨停；文化传媒板块拉升，中信出版、龙版传媒、新华都、中国出版涨停；金属铜板块震荡走强，精艺股份涨停；房地产板块集体上涨，深物业A、盈新发展、我爱我家涨停。　　截至午间收盘，沪指涨0.36%，深证成指涨0.05%，创业板指跌0.15%，科创50指数跌0.42%。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908334215.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908334215.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260908/32363122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002295","BK0012","516550","000011","BK0216","BK0229","BK0127","03147","BK0164","000001","BK0199","BK0105","600354","LU1781817850.SGD","603127","BK0092","LU1993786604.SGD","BK0157","BK0278","BK0248","LU0067412154.USD","601952","605077","BK0187","000930","BK0104","BK0233","600108","BK0173","BK0238","LU1226287529.USD","000560","BK0183","LU1580142542.USD","BK0188","399006","BK0227","BK0077","BK0273","LU0880133367.SGD","BK0007","06127","BK0201","LU1655091616.SGD","BK0010","BK0186","LU0501845795.SGD","IE00B0JY6N72.USD","07234","BK0190","BK0028","BK0082","LU0072913022.USD","BK0102","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665344534","title":"直击昭衍新药业绩说明会：高管回应净利润大增、主业亏损等问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2665344534","media":"大河财立方","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665344534?lang=zh_cn&edition=full","pubTime":"2026-09-08 12:02","pubTimestamp":1788840164,"startTime":"0","endTime":"0","summary":"【大河财立方记者吴春波】9月8日，昭衍新药（603127.SH/06127.HK）通过上证路演中心召开2026年半年度业绩说明会。公司董事、总经理兼董事会秘书高大鹏，就投资者关心的净利润大增、主营业务亏损、订单增长及实验猴价格走势等问题进行了集中回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083867884147.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083867884147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06127","603127"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2437},{"period":"1month","weight":0.1474},{"period":"3month","weight":0.5571},{"period":"6month","weight":0.4652},{"period":"1year","weight":0.2336},{"period":"ytd","weight":0.3485}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0761},{"period":"6month","weight":-0.0047},{"period":"1year","weight":-0.0507},{"period":"ytd","weight":-0.0311}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。该公司通过三个分部开展业务。药物非临床研究服务分部主要提供药品非临床安全性评价服务、药效学研究服务、药代动力学研究服务。临床服务及其他分部主要提供药品上市前的临床服务以及药物警戒服务。实验模型供应分部为实验模型及其附属产品的生产和销售。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.052852},{"month":2,"riseRate":0.6,"avgChangeRate":0.086368},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020373},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.07562},{"month":5,"riseRate":0.666667,"avgChangeRate":0.065576},{"month":6,"riseRate":0.666667,"avgChangeRate":0.063039},{"month":7,"riseRate":0.833333,"avgChangeRate":0.119134},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.109974},{"month":9,"riseRate":0.666667,"avgChangeRate":0.034632},{"month":10,"riseRate":0.2,"avgChangeRate":-0.062964},{"month":11,"riseRate":0.4,"avgChangeRate":0.019565},{"month":12,"riseRate":0.6,"avgChangeRate":0.001933}],"exchange":"SEHK","name":"昭衍新药","nameEN":"JOINN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,06127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}